Scholarlink

Introduction <p>Psoriasis (PsO) is a common inflammatory dermatological condition with a substantial negative impact on patient quality of life. Several biological agents are available for the treatment of PsO, and clinicians and patients must consider various factors when deciding on the most appropriate biological agent.</p> Methods <p>Here, we report a set of consensus statements developed by an Italian PsO advisory board on use of the anti-interleukin-17A biological secukinumab in routine clinical practice.</p> Results <p>The statements were developed under three main topics, the first of which was “characteristics of secukinumab and criteria for patient selection to achieve long-term benefits”. This statement helps to identify patients most likely to benefit from secukinumab, including biological-naïve patients with moderate PsO; patients with PsO involving sensitive sites; patients in whom biosimilar anti-tumour necrosis factor-alpha treatment has proved ineffective; patients at high risk of developing psoriatic arthritis; lean or normal-weight patients; patients with active disease receiving conventional disease-modifying antirheumatic drugs; and patients with comorbidities, including cardiovascular disease. Under the second topic, “strategies to maintain secukinumab effectiveness in the long term”, the advisors highlighted the importance of patient support to promote adherence; weight control; understanding that PsO can worsen for reasons unrelated to treatment; and understanding that appropriate treatment should depend on the severity of any disease worsening. The third topic, “strategies for patient support to promote adherence to therapy”, noted the importance of patient education, accurate disease assessments and treatment tailoring.</p> Conclusion <p>These consensus statements will help guide dermatologists in the selection of patients with PsO for whom secukinumab is the most appropriate treatment in real-world clinical practice in Italy.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Strategies for Optimal Use of Biological Therapies in Managing Psoriasis: Focus on Secukinumab

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年9月4日

查看全文
  • Anna Balato,
  • Martina Burlando,
  • Anna Campanati,
  • Antonio Costanzo,
  • Andrea Chiricozzi,
  • Paolo Gisondi,
  • Piergiorgio Malagoli,
  • Giuseppe Micali,
  • Chiara Astrua,
  • Nicoletta Bernardini,
  • Tommaso Bianchelli,
  • Cinzia Buligan,
  • Domenico D’Amico,
  • Luisa Di Costanzo,
  • Claudia Leporati,
  • Cristina Mugheddu,
  • Maria Letizia Musumeci,
  • Alessandra Narcisi,
  • Gianluca Pagnanelli,
  • Lucia Pietroleonardo,
  • Lidia Sacchelli,
  • Davide Strippoli,
  • Emanuele Trovato

摘要

Introduction

Psoriasis (PsO) is a common inflammatory dermatological condition with a substantial negative impact on patient quality of life. Several biological agents are available for the treatment of PsO, and clinicians and patients must consider various factors when deciding on the most appropriate biological agent.

Methods

Here, we report a set of consensus statements developed by an Italian PsO advisory board on use of the anti-interleukin-17A biological secukinumab in routine clinical practice.

Results

The statements were developed under three main topics, the first of which was “characteristics of secukinumab and criteria for patient selection to achieve long-term benefits”. This statement helps to identify patients most likely to benefit from secukinumab, including biological-naïve patients with moderate PsO; patients with PsO involving sensitive sites; patients in whom biosimilar anti-tumour necrosis factor-alpha treatment has proved ineffective; patients at high risk of developing psoriatic arthritis; lean or normal-weight patients; patients with active disease receiving conventional disease-modifying antirheumatic drugs; and patients with comorbidities, including cardiovascular disease. Under the second topic, “strategies to maintain secukinumab effectiveness in the long term”, the advisors highlighted the importance of patient support to promote adherence; weight control; understanding that PsO can worsen for reasons unrelated to treatment; and understanding that appropriate treatment should depend on the severity of any disease worsening. The third topic, “strategies for patient support to promote adherence to therapy”, noted the importance of patient education, accurate disease assessments and treatment tailoring.

Conclusion

These consensus statements will help guide dermatologists in the selection of patients with PsO for whom secukinumab is the most appropriate treatment in real-world clinical practice in Italy.